Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Abstract:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present data from its clinical trial evaluating NBTXR3 in advanced soft tissue sarcoma.

Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Paris, France | Posted on April 2nd, 2014

The clinical trial will be presented during the congress session dedicated to sarcoma.

This year's ASCO will take place in Chicago from 31 May to 3 June, 2014. The Annual Meeting brings together more than 25,000 oncology professionals from a broad range of clinical research specialties.

The NBTXR3 study was selected from over 5,500 abstracts received by the Scientific Program Committee of ASCO for review.

Laurent Levy, CEO of Nanobiotix said: "We are honored that ASCO has invited us to present our NBTXR3 data in front of the international oncology community. This is an encouraging step for our team and our partners and we will continue to develop innovative therapies aimed to improve patient care in the fight against cancer."

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

Disclaimer

This press release and the information contained therein do not constitute an offer of securities for sale or any solicitation to purchase or subscribe for Nanobiotix's shares in any jurisdiction. The distribution of this press release in certain jurisdictions may constitute a breach of applicable laws and regulations. Therefore, individuals who are located in such jurisdictions where this press release is issued, published or distributed must seek information and comply with such laws and regulations.

For more information, please click here

Contacts:
Nanobiotix
Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53



Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59



Instinctif Partners (formerly College Hill)
Media relations (Outside France)
Melanie Toyne Sewell / Donia Al Saffar / Katherine Lynch
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Roll up your screen and stow it away? Tel Aviv University researchers develop molecular backbone of super-slim, bendable digital displays March 30th, 2015

Princess Margaret scientists convert microbubbles to nanoparticles: Harnessing light to advance tumor imaging, provide platform for targeted treatment March 30th, 2015

Wrapping carbon nanotubes in polymers enhances their performance: Scientists at Japan's Kyushu University say polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy applications March 30th, 2015

Tokyo Institute of Technology research: Catalyst redefines rate limitations in ammonia production March 30th, 2015

Nanomedicine

Princess Margaret scientists convert microbubbles to nanoparticles: Harnessing light to advance tumor imaging, provide platform for targeted treatment March 30th, 2015

Wrapping carbon nanotubes in polymers enhances their performance: Scientists at Japan's Kyushu University say polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy applications March 30th, 2015

'Atomic chicken-wire' is key to faster DNA sequencing March 30th, 2015

Novel nanoparticle therapy promotes wound healing March 27th, 2015

Announcements

Princess Margaret scientists convert microbubbles to nanoparticles: Harnessing light to advance tumor imaging, provide platform for targeted treatment March 30th, 2015

Wrapping carbon nanotubes in polymers enhances their performance: Scientists at Japan's Kyushu University say polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy applications March 30th, 2015

Tokyo Institute of Technology research: Catalyst redefines rate limitations in ammonia production March 30th, 2015

Next important step toward quantum computer: Scientists at the University of Bonn have succeeded in linking 2 different quantum systems March 30th, 2015

Events/Classes

State-of-the-art online system unveiled to pinpoint metrology software accuracy March 27th, 2015

LAMDAMAP 2015 hosted by the University March 26th, 2015

SUNY POLY CNSE to Host First Ever Northeast Semi Supply Conference (NESCO) Conference Will Connect New and Emerging Innovators in the Northeastern US and Canada with Industry Leaders and Strategic Investors to Discuss Future Growth Opportunities in NYS March 25th, 2015

NNI Publishes Workshop Report Assessing the Status of EHS Risk Science: Report examines progress three years after the release of the 2011 NNI EHS Research Strategy March 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE